We love our portfolio companies.

You’ll love working for one of them.
Leverage our network to build your career.
Tell us about yourself to get matched with companies in our portfolio with opportunities that align with your career goals.
Triumvira Immunologics
Triumvira Immunologics

Triumvira Immunologics is a biotechnology company developing a novel platform for engineering T cells to attack cancers. In order to do this, we, like others, remove white blood cells from patients, use genetic engineering to direct T cells, which are an important component of the immune system, to recognize a protein found on the surface of certain cancer cells. We then expand these reprogrammed T cells so they can be administered back to the patient, where they will find the cancer cells and kill them. We believe our innovative and proprietary technology, called the T cell-Antigen Coupler (or TAC), possesses advantages over other approaches because of the nature of the TAC construct. Triumvira has licensed the TAC technology from the laboratory of Jonathan Bramson, PhD, of McMaster University in Hamilton, Ontario and we are currently supporting a broad research effort in Dr. Bramson's lab. Our team is continuing to explore the biology and potential of TAC-T cells, developing TACs against a variety of cancer targets, and scaling up the manufacturing process. Our goal is to begin human testing of TAC T cells by the end of 2017. Our team and our network of academic and industry consultants brings broad industry experience and deep scientific understanding to the TAC program.
Austin, TX, USA, Hackensack, NJ, USA
Founded in 2015
Inaccurate data? Flag it here.
Open jobs at Triumvira Immunologics
We only use strictly necessary, first-party cookies on this job board. These are cookies that are necessary to deliver this service to you, or are necessary for B Capital Group to understand how it is being used. Read our Cookie Policy.